PABLO LUIS
ORTIZ ROMERO
Catedrático de universidad
University of Sydney
Sídney, AustraliaPublicaciones en colaboración con investigadores/as de University of Sydney (5)
2021
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 5, pp. 643-654
-
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
European Journal of Cancer, Vol. 158, pp. 156-168
-
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data
Blood Advances, Vol. 5, pp. 5098-5106
-
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
European Journal of Cancer, Vol. 148, pp. 411-421
2017
-
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
The Lancet, Vol. 390, Núm. 10094, pp. 555-566